BLLN

BillionToOne, Inc.

November 5, 2026 · pre-market

Rarity

2.06

Peak move

−11.50%

Float cap

$2.2B

BillionToOne is a molecular diagnostics company that uses a single-molecule next-generation sequencing platform to detect and quantify genetic targets in cell-free DNA from a blood draw. It develops prenatal tests, including UNITY for fetal risk assessment, and oncology liquid biopsy tests, Northstar Select and Northstar Response, for therapy selection and treatment monitoring. Its tests are sold to physicians, clinics, and healthcare providers to guide patient care.